Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N, Hale PM; Repaglinide/Rosiglitazone Study Group.

Diabet Med. 2004 Apr;21(4):329-35.

PMID:
15049934
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.

Raskin P.

Diabetes Obes Metab. 2008 Dec;10(12):1167-77. doi: 10.1111/j.1463-1326.2008.00907.x. Epub 2008 May 20. Review.

PMID:
18494804
4.

Repaglinide in combination therapy.

Moses R.

Diabetes Nutr Metab. 2002 Dec;15(6 Suppl):33-8. Review.

PMID:
12702006
5.

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Culy CR, Jarvis B.

Drugs. 2001;61(11):1625-60. Review.

PMID:
11577798
7.

Repaglinide as monotherapy in Type 2 diabetes.

Gomis R.

Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S133-5. Review.

PMID:
10522838
8.

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.

Owens DR.

Diabet Med. 1998;15 Suppl 4:S28-36. Review.

PMID:
9868989
9.

Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.

Johansen OE, Birkeland KI.

Am J Cardiovasc Drugs. 2007;7(5):319-35. Review.

PMID:
17953471
10.
11.

Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.

Guay DR.

Pharmacotherapy. 1998 Nov-Dec;18(6):1195-204. Review.

PMID:
9855316
12.

[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].

Rutten GE.

Ned Tijdschr Geneeskd. 2001 Aug 11;145(32):1547-50. Review. Dutch.

PMID:
11525087
13.

Repaglinide: prandial glucose regulation in clinical practice.

Owens DR, McDougall A.

Diabetes Obes Metab. 2000 Mar;2 Suppl 1:S43-8. Review.

PMID:
11225759
14.

[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].

Kellerer M, Jakob S, Linn T, Haslbeck M.

MMW Fortschr Med. 2003 Dec 18;145(51-52):I-X; quiz XI-XII. Review. German. No abstract available.

PMID:
14974337
15.

[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?

[No authors listed]

Drug Ther Bull. 2003 Jul;41(7):52-4. Review.

PMID:
12879789
16.

Combination therapy in type 2 diabetes: the role of repaglinide.

Moses R.

J Assoc Physicians India. 2001 Jan 25;49 Spec No:62-8. Review. No abstract available.

PMID:
11235608
17.

The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.

Owens D.

J Assoc Physicians India. 2001 Jan 25;49 Spec No:54-61. Review. No abstract available.

PMID:
11235607
18.

Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.

F├╝chtenbusch M, Standl E, Schatz H.

Exp Clin Endocrinol Diabetes. 2000;108(3):151-63. Review.

PMID:
10926309
19.

Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.

Owens DR.

Eur J Clin Invest. 1999 Jun;29 Suppl 2:30-7. Review.

PMID:
10383608
20.

Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.

Yin J, Deng H, Qin S, Tang W, Zeng L, Zhou B.

Diabetes Res Clin Pract. 2014 Sep;105(3):e10-5. doi: 10.1016/j.diabres.2014.06.009. Epub 2014 Jun 23. Review.

PMID:
25005849

Supplemental Content

Support Center